UNCY
Closed
Unicycive Therapeutics Inc
0.3541
0.0000 (0.00%)
Last Update: 06 Sep 2024 23:24:00
Yesterday: 0.3541
Day's Range: 0.348 - 0.361
Send
sign up or login to leave a comment!
When Written:
2.11
Unicycive Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing novel therapies for the treatment of rare and orphan diseases. The company is headquartered in Durham, North Carolina, and was founded in 2015.
Unicycive Therapeutics is focused on developing small molecule drugs that target specific genetic mutations that cause rare diseases. The company's lead drug candidate, UNI9109, is being developed for the treatment of patients with cystic fibrosis who have certain genetic mutations.
The company's approach is based on the concept of "unicyclic molecules," which are small, stable compounds that can be designed to target specific genetic mutations. Unicycive Therapeutics is also developing a pipeline of other drug candidates for the treatment of rare diseases, including lysosomal storage disorders and other genetic diseases.
Unicycive Therapeutics has received funding from various sources, including venture capital firms and grants from the National Institutes of Health. The company is led by a team of experienced biotech executives and scientists.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Unicycive Therapeutics is focused on developing small molecule drugs that target specific genetic mutations that cause rare diseases. The company's lead drug candidate, UNI9109, is being developed for the treatment of patients with cystic fibrosis who have certain genetic mutations.
The company's approach is based on the concept of "unicyclic molecules," which are small, stable compounds that can be designed to target specific genetic mutations. Unicycive Therapeutics is also developing a pipeline of other drug candidates for the treatment of rare diseases, including lysosomal storage disorders and other genetic diseases.
Unicycive Therapeutics has received funding from various sources, including venture capital firms and grants from the National Institutes of Health. The company is led by a team of experienced biotech executives and scientists.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!